《異動股》中國同輻(01763.HK)續漲18%創上市新高 成交增
中國同輻(01763.HK)突破今年1月所創上市高位24.6元,最高見26.3元,現造25.95元,續揚18%,一向薄弱成交倍增至235萬股,涉資5,553萬元。
同輻為內地大型顯像診斷與治療用放射性藥品,尿素呼氣試驗藥盒和測試儀及放射免疫分析藥盒製造商。股份於2018年7月以每股21.6元來港上市,淨籌約16.1億元。
該公司上周四公布,與內地生態環境部核與輻射安全中心簽訂輻射安全與環境保護合作框架協議,雙方將共同合作申報在輻射安全、環境保護等方面的合作項目,爭取國家及地方各類財政經費支持,支撐開展核技術利用輻射安全相關研究。同時,雙方可於核技術利用輻射安全及相關領域開展技術支持與合作,合作範圍包括但不限於核技術利用輻射安全關鍵技術研究、放射源安全管理和應用、放射性物品運輸、輻射環境監測、專業培訓、技術諮詢與服務、核技術利用輻射安全科普等領域等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.